Last €0.17 EUR
Change Today -0.032 / -15.76%
Volume 7.5K
A5Y On Other Exchanges
Symbol
Exchange
A5Y is not on other exchanges.
As of 9:29 AM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

affymax inc (A5Y) Snapshot

Open
€0.16
Previous Close
€0.20
Day High
€0.17
Day Low
€0.13
52 Week High
09/2/13 - €1.20
52 Week Low
06/25/14 - €0.06
Market Cap
6.4M
Average Volume 10 Days
14.8K
EPS TTM
--
Shares Outstanding
37.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AFFYMAX INC (A5Y)

affymax inc (A5Y) Related Businessweek News

No Related Businessweek News Found

affymax inc (A5Y) Details

Affymax, Inc. operates as a biopharmaceutical company in the United States. The company was founded in 2001 and is based in Cupertino, California.

2 Employees
Last Reported Date: 07/31/14
Founded in 2001

affymax inc (A5Y) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $12.1K
President
Total Annual Compensation: --
Chief Financial Officer and Secretary
Total Annual Compensation: $97.5K
Chief Medical Officer
Total Annual Compensation: $452.1K
Chief Accounting Officer and Vice President o...
Total Annual Compensation: $63.4K
Compensation as of Fiscal Year 2013.

affymax inc (A5Y) Key Developments

Affymax, Inc. Announces Unaudited Consolidated Earnings Results for Second Quarter and Six Months Ended June 30, 2014

Affymax, Inc. announced unaudited consolidated earnings results for second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $42,000, loss from operations of $953,000, income before provision for income taxes of $7,209,000, net income and comprehensive income of $7,209,000 or $0.19 per basic and diluted share compared to the total revenue of $525,000, income from operations of $14,271,000, income before provision for income taxes of $13,214,000, net income and comprehensive income of $15,372,000 or $0.41 per basic and diluted share for the same quarter a year ago. For the year to date, the company reported total revenue of $42,000, loss from operations of $2,345,000, income before provision for income taxes of $5,817,000, net income and comprehensive income of $5,817,000 or $0.16 per basic and diluted share compared to the total revenue of $1,369,000, loss from operations of $12,297,000, loss before provision for income taxes of $13,831,000, net loss and comprehensive income of $11,673,000 or $0.31 per basic and diluted share for the same period a year ago.

Affymax Terminates Omontys' Product Collaboration and License Agreement with Takeda Pharmaceutical Company, Effective September 10, 2014

Affymax revealed the termination of its Omontys (peginesatide) product collaboration and license agreement with Takeda Pharmaceutical Company, effective September 10, 2014. Under a previous agreement, Affymax and Takeda voluntarily recalled all lots of Omontys and suspended promotional activities in the US upon postmarketing reports of serious hypersensitivity reactions including anaphylaxis, which may be life-threatening or fatal. Based on the postmarketing reports and related discussions with Takeda, Affymax has elected not to exercise its rights with respect to the Omontys New Drug Application.

Affymax and Takeda Announce Termination of Omontys(R) (peginesatide) Product Collaboration and License Agreement

Affymax, Inc. and Takeda Pharmaceutical Company Limited announced that their Omontys(R) (peginesatide) product collaboration and license agreement will terminate effective September 10, 2014. In February 2013, Affymax and Takeda voluntarily recalled all lots of Omontys and suspended promotional activities in the U.S. following postmarketing reports of serious hypersensitivity reactions including anaphylaxis, which may be life-threatening or fatal. Takeda has conducted a detailed investigation of these reactions. The investigation has confirmed no quality or manufacturing issues were present but has not identified a specific root cause for the reactions that were observed. Based on these findings and related discussions with Takeda, Affymax has elected not to exercise its rights with respect to the Omontys New Drug Application (NDA). Takeda will work with the U.S. Food and Drug Administration to withdraw the Omontys NDA. The Board of Directors of Affymax is reviewing its strategic options as a result of the termination of the collaboration with Takeda.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
A5Y:GR €0.17 EUR -0.032

A5Y Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for A5Y.
View Industry Companies
 

Industry Analysis

A5Y

Industry Average

Valuation A5Y Industry Range
Price/Earnings 2.7x
Price/Sales 196.4x
Price/Book 1.6x
Price/Cash Flow 2.7x
TEV/Sales 115.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AFFYMAX INC, please visit www.affymax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.